China Cell And Gene Therapy Cdmo Market Size & Outlook
China cell and gene therapy cdmo market, 2018-2030 (US$M)
Related Markets
China cell and gene therapy cdmo market highlights
- The China cell and gene therapy cdmo market generated a revenue of USD 756.7 million in 2023 and is expected to reach USD 4,479.3 million by 2030.
- The China market is expected to grow at a CAGR of 28.9% from 2024 to 2030.
- In terms of segment, pre-clinical was the largest revenue generating by phase in 2023.
- Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2023 | USD 756.7 million |
| Market revenue in 2030 | USD 4,479.3 million |
| Growth rate | 28.9% (CAGR from 2023 to 2030) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, China accounted for 15.2% of the global cell and gene therapy cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,802.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.2% in 2023. Horizon Databook has segmented the China cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Some of the key companies providing CDMO services for pharmaceuticals in China are WuXi STA; Catalent, Inc.; AbbVie; and Lonza. The expansion of key players in China cell & gene therapy CDMO market has positively impacted the services’ quality, ensuring that the products manufactured meet the highest quality & safety standards.
For instance, in February 2023, Porton Advanced Solutions and Yinjia Biosciences partnered to advance cell and gene therapies. Yinjia will supply core protein raw materials and testing reagents to enhance Porton’s cell & gene therapy CDMO capabilities, aiding in innovative therapeutics development.
Reasons to subscribe to China cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into China cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China cell and gene therapy cdmo market size, by by phase, 2018-2030 (US$M)
China Cell And Gene Therapy CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
